Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2476
CALL
Unity
U
$19.2B
| $3.52M | ﹤0.01% |
79,800
+29,800
| +60% | +$1.21M |
2025 Q3
1 quarter
|
|
|
NIQ
2477
NIQ Global Intelligence PLC
NIQ
$4.91B
| $3.52M | ﹤0.01% |
213,467
+212,998
| +45,415% | +$3.12M |
2025 Q3
1 quarter
|
|
2478
IDT Corp
IDT
$1.96B
| $3.51M | ﹤0.01% |
68,552
-23,125
| -25% | -$1.16M |
2016 Q2
38 quarters
|
|
2479
Innospec
IOSP
$2.4B
| $3.51M | ﹤0.01% |
45,848
-493
| -1% | -$37.2K |
2016 Q1
39 quarters
|
|
2480
Relay Therapeutics
RLAY
$4.15B
| $3.5M | ﹤0.01% |
414,143
-47,736
| -10% | -$341K |
2022 Q1
15 quarters
|
|
2481
Ingevity
NGVT
$2.49B
| $3.5M | ﹤0.01% |
59,105
+4,220
| +8% | +$229K |
2016 Q2
38 quarters
|
|
2482
First Majestic Silver
AG
$8.71B
| $3.5M | ﹤0.01% |
209,951
-1,173,452
| -85% | -$16.3M |
2024 Q3
5 quarters
|
|
|
HI
2483
DELISTED
Hillenbrand
HI
| $3.49M | ﹤0.01% |
110,170
+10,673
| +11% | +$329K |
2013 Q2
50 quarters
|
|
2484
Monro
MNRO
$443M
| $3.49M | ﹤0.01% |
174,235
+7,499
| +4% | +$138K |
2016 Q2
38 quarters
|
|
2485
National Bank Holdings
NBHC
$1.69B
| $3.49M | ﹤0.01% |
91,844
+21,531
| +31% | +$811K |
2016 Q2
38 quarters
|
|
2486
The GEO Group
GEO
$4.13B
| $3.48M | ﹤0.01% |
216,176
-58,012
| -21% | -$967K |
2014 Q3
45 quarters
|
|
2487
Coty
COTY
$2.34B
| $3.48M | ﹤0.01% |
1,130,139
-287,658
| -20% | -$1.05M |
2015 Q1
43 quarters
|
|
2488
Ducommun
DCO
$2.65B
| $3.48M | ﹤0.01% |
36,588
+2,594
| +8% | +$242K |
2013 Q2
50 quarters
|
|
2489
Kodiak Sciences
KOD
$5.94B
| $3.48M | ﹤0.01% |
124,334
+55,485
| +81% | +$1.14M |
2019 Q1
27 quarters
|
|
|
HTO
2490
H2O America
HTO
$2.52B
| $3.46M | ﹤0.01% |
70,565
+7,861
| +13% | +$377K |
2019 Q1
27 quarters
|
|
2491
Northwest Bancshares
NWBI
$2.22B
| $3.45M | ﹤0.01% |
287,451
+60,756
| +27% | +$739K |
2016 Q1
39 quarters
|
|
2492
Capricor Therapeutics
CAPR
$520M
| $3.45M | ﹤0.01% |
119,372
+64,279
| +117% | +$839K |
2024 Q2
6 quarters
|
|
2493
Interface
TILE
$2.02B
| $3.43M | ﹤0.01% |
122,921
+8,057
| +7% | +$220K |
2016 Q1
39 quarters
|
|
2494
Teladoc Health
TDOC
$1B
| $3.43M | ﹤0.01% |
489,982
-48
| -0% | -$376 |
2015 Q3
41 quarters
|
|
2495
OR Royalties Inc
OR
$6.46B
| $3.42M | ﹤0.01% |
96,706
+6,576
| +7% | +$230K |
2022 Q1
15 quarters
|
|
2496
Quaker Houghton
KWR
$2.77B
| $3.42M | ﹤0.01% |
24,898
+1,601
| +7% | +$216K |
2013 Q2
50 quarters
|
|
|
KKR.PRD
2497
KKR & Co 6.25% Series D Preferred Stock
KKR.PRD
$2.12B
| $3.42M | ﹤0.01% |
65,893
-43,987
| -40% | -$2.23M |
2025 Q1
3 quarters
|
|
2498
CALL
AdvisorShares Pure US Cannabis ETF
MSOS
$864M
| $3.41M | ﹤0.01% |
+722,900
| New | +$3.22M |
2025 Q4
0 quarters
|
|
2499
Northwest Natural Holdings
NWN
$1.99B
| $3.41M | ﹤0.01% |
72,868
+6,046
| +9% | +$282K |
2013 Q2
50 quarters
|
|
2500
Azenta
AZTA
$1.7B
| $3.41M | ﹤0.01% |
102,398
-54,335
| -35% | -$1.78M |
2013 Q2
50 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.